Lead Product(s) : Revefenacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : YUPELRI® (revefenacin) inhalation solution is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Brand Name : Yupelri
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2023
Lead Product(s) : Revefenacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol is the first generic version of AstraZeneca's Symbicort drug-device combination product and is indicated for certain patients with asthma or chronic obstructive pulmonary disease...
Brand Name : Breyna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 31, 2023
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Kindeva Drug Delivery
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Breyna (Budesonide and Formoterol Fumarate Dihydrate), first approved generic version of AstraZeneca's Symbicort, a drug-device combination product, is indicated for certain patients with asthma or COPD and will be available in 160 /4.5 and 80/4.5 mcg do...
Brand Name : Breyna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2022
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Kindeva Drug Delivery
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves First Generic of Symbicort to Treat Asthma and COPD
Details : U.S.FDA approved generic budesonide and formoterol fumarate dihydrate aerosol for treatment of two pulmonary health conditions: asthma in patients six years of age and older; and maintenance treatment of airflow obstruction and reducing exacerbations for...
Brand Name : Budesonide/Formoterol Fumarate Dihydrate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2022
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Kindeva Drug Delivery
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Tentative Approval to Generic Version of Symbicort
Details : The U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first generic version of Symbicort based on an Abbreviated New Drug Application (ANDA).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 09, 2021
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Kindeva Drug Delivery
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?